Title:
CD20 BINDING SINGLE DOMAIN ANTIBODIES
Document Type and Number:
Japanese Patent JP2023040247
Kind Code:
A
Abstract:
To provide a CD20 binding agent that binds to CD20 positive cells such as cancer, to result in the death of the cells.SOLUTION: The present invention provides a CD20 binding agent that comprises at least one targeting moiety comprising three complementarity determining regions (CDR1, CDR2 and CDR3), the three complementarity determining regions each comprising an amino acid sequence selected from any one of a specific sequence group. In an embodiment, the targeting moiety is a single domain antibody (VHH or Nanobody). In some embodiments, these CD20 binding agents bind to, but do not functionally modulate (e.g. partially or fully neutralize) CD20. In some embodiments, the CD20 binding agent binds to CD20 positive cells to result in death of the CD20 positive cells.SELECTED DRAWING: None
Inventors:
Taverniel, Jean
Cowwells, Angers
Van der Heiden, Jose
Cowwells, Angers
Van der Heiden, Jose
Application Number:
JP2023003750A
Publication Date:
March 22, 2023
Filing Date:
January 13, 2023
Export Citation:
Assignee:
Buoy Ivy Buisette W
Universal Ghent
Universal Ghent
International Classes:
A61K47/68; A61K31/704; A61K33/24; A61K33/243; A61K38/19; A61K38/20; A61K38/21; A61K39/395; A61K45/00; A61K45/06; A61P1/00; A61P1/04; A61P1/16; A61P1/18; A61P3/02; A61P3/10; A61P7/04; A61P7/06; A61P9/10; A61P11/00; A61P11/06; A61P13/12; A61P17/00; A61P17/04; A61P19/02; A61P19/08; A61P21/00; A61P25/00; A61P29/00; A61P31/00; A61P31/18; A61P31/22; A61P35/00; A61P35/02; A61P37/02; A61P37/08; A61P43/00; C07K16/28
Attorney, Agent or Firm:
Ryoichi Takaoka
Nao Oda
Akiyo Iwahori
Kamoto Takahashi
Nao Oda
Akiyo Iwahori
Kamoto Takahashi